Azmy Ghaly
Geriatric Medicine · Los Angeles, CANPI 1194899336
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. Among geriatric medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$442
- Lilly USA, LLC$435
- Johnson & Johnson$380
- Bayer$357
- Sunovion Pharmaceuticals Inc.$297
- AbbVie$212
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,49398%
- Education$882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $442 |
| Lilly USA, LLC | 18 | $435 |
| Johnson & Johnson | 13 | $380 |
| Bayer | 15 | $357 |
| Sunovion Pharmaceuticals Inc. | 16 | $297 |
| AbbVie(2 entities) | 11 | $212 |
| Pfizer | 6 | $139 |
| Merck | 7 | $137 |
| Novartis | 6 | $128 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $127 |
| Amgen | 5 | $117 |
| Vanda Pharmaceuticals Inc. | 3 | $73 |
| Mannkind Corporation | 2 | $68 |
| Lundbeck LLC | 3 | $67 |
| Avanir Pharmaceuticals, Inc. | 3 | $60 |
| Boehringer Ingelheim | 2 | $58 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
| Astellas Pharma US Inc | 2 | $45 |
| GSK | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Abiomed | 1 | $35 |
| Dexcom, Inc. | 2 | $34 |
| Corcept Therapeutics | 1 | $29 |
| Exact Sciences | 1 | $24 |
| Neurelis, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Smith+Nephew | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Medtronic | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$117
How this compares
$3,581 in reported general payments places this provider in the 90th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 30 | $163,812 |
| SantylCollagenase Clostridium Hist. | 28 | $106,197 |
| EliquisApixaban | 304 | $84,057 |
| JardianceEmpagliflozin | 99 | $32,818 |
| Sevelamer Hcl | 43 | $32,473 |
| XareltoRivaroxaban | 98 | $32,300 |
| JanuviaSitagliptin Phosphate | 55 | $23,348 |
| XifaxanRifaximin | 17 | $21,986 |
| Pantoprazole Sodium | 249 | $18,011 |
| Atorvastatin Calcium | 828 | $13,490 |
| OzempicSemaglutide | 13 | $13,382 |
| EntrestoSacubitril/Valsartan | 35 | $12,644 |
| EpogenEpoetin Alfa | 30 | $11,567 |
| TradjentaLinagliptin | 35 | $9,025 |
| Levetiracetam | 176 | $7,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $442 | $163,81230 claims |
| Smith+NephewSantyl | $24 | $106,19728 claims |
| PfizerEliquis | $139 | $84,057304 claims |
| Boehringer IngelheimJardiance, Tradjenta | $58 | $41,842134 claims |
| Johnson & JohnsonXarelto | $380 | $32,30098 claims |
| MerckJanuvia | $137 | $23,34855 claims |
| Novo NordiskOzempic | $12 | $13,38213 claims |
| NovartisEntresto | $128 | $12,64435 claims |
| AmgenEpogen | $117 | $11,56730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in Los Angeles
- Wayne ChenLos Angeles$40K
- Arman HekmatiLos Angeles$14K
- Dong LeeLos Angeles$7K
- Sylvia CarlisleLos Angeles$4K
- Joshua ChodoshLos Angeles$4K
- Jo Ann PullenLos Angeles$3K
- Robert FeldmanLaguna Hills$1.2M
- Oscar ChienSan Gabriel$208K
- Anders NybergSan Diego$160K
- Paul AisenSan Diego$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.